These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 11386046)

  • 1. [Insisting on intravenous polyvalent immunoglobulin therapy in polymyositis in spite of the occurrence of sever hemolytic anemia].
    Ballot-Brossier C; Mortelecque R; Sinègre M; Marceau A; Dauriat G; Courtois F
    Transfus Clin Biol; 2001 Apr; 8(2):94-9. PubMed ID: 11386046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose intravenous immunoglobulin is strongly associated with hemolytic anemia in patients with Kawasaki disease.
    Nolan BE; Wang Y; Pary PP; Luban NLC; Wong ECC; Ronis T
    Transfusion; 2018 Nov; 58(11):2564-2571. PubMed ID: 30265742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute hemolysis after high-dose intravenous immunoglobulin therapy in highly HLA sensitized patients.
    Kahwaji J; Barker E; Pepkowitz S; Klapper E; Villicana R; Peng A; Chang R; Jordan SC; Vo AA
    Clin J Am Soc Nephrol; 2009 Dec; 4(12):1993-7. PubMed ID: 19833910
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Results and long-term followup of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirty-five adult patients.
    Cherin P; Pelletier S; Teixeira A; Laforet P; Genereau T; Simon A; Maisonobe T; Eymard B; Herson S
    Arthritis Rheum; 2002 Feb; 46(2):467-74. PubMed ID: 11840450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hemolysis upon intravenous immunoglobulin transfusion.
    Padmore RF
    Transfus Apher Sci; 2012 Feb; 46(1):93-6. PubMed ID: 22169381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hemolytic anemia associated with intravenous immunoglobulin.
    Wilson JR; Bhoopalam H; Fisher M
    Muscle Nerve; 1997 Sep; 20(9):1142-5. PubMed ID: 9270670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Don't neglect the rare adverse event with intravenous immunoglobulin: Hemolytic anemia.
    Ucar İ; Koyuncu MB; Solmaz AA; Ugurludogan AC; Mercan S; Kucuk M; Unal T; Mazman S; Atilla E
    Transfus Clin Biol; 2023 Feb; 30(1):11-15. PubMed ID: 36028153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous gamma globulin as first line therapy in polymyositis and dermatomyositis: an open study in 11 adult patients.
    Cherin P; Piette JC; Wechsler B; Bletry O; Ziza JM; Laraki R; Godeau P; Herson S
    J Rheumatol; 1994 Jun; 21(6):1092-7. PubMed ID: 7932419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous immunoglobulin therapy for refractory myositis.
    Moriguchi M; Suzuki T; Tateishi M; Hara M; Kashiwazaki S
    Intern Med; 1996 Aug; 35(8):663-7. PubMed ID: 8894745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hemolytic anemia following high dose intravenous immunoglobulin in patients with chronic neurological disorders.
    Markvardsen LH; Christiansen I; Harbo T; Jakobsen J
    Eur J Neurol; 2014; 21(1):147-52. PubMed ID: 24180709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regression of Kaposi's sarcoma after intravenous immunoglobulin treatment for polymyositis.
    Carmeli Y; Mevorach D; Kaminski N; Raz E
    Cancer; 1994 Jun; 73(11):2859-61. PubMed ID: 8194027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Intravenous immunoglobulins in the treatment of polymyositis and dermatomyositis].
    Cherin P
    Ann Med Interne (Paris); 2000 May; 151 Suppl 1():1S48-50. PubMed ID: 10896990
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prospective observational study of the incidence, natural history, and risk factors for intravenous immunoglobulin-mediated hemolysis.
    Pendergrast J; Armali C; Callum J; Cserti-Gazdewich C; Jiwajee A; Lieberman L; Lau W; Lin Y; Parmar N; Pavenski K; Riden LS; Shehata N; Willie-Ramharack K; Tomlinson G; Tong TN; Binnington B; Branch DR;
    Transfusion; 2021 Apr; 61(4):1053-1063. PubMed ID: 33433931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenous immunoglobulin-induced hemolytic anemia in a patient with juvenile dermatomyositis.
    Clemenz MR; McGowan Iv JW; Shuler MJ; Lynn AW
    J Drugs Dermatol; 2013 Jan; 12(1):111-3. PubMed ID: 23377338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Intravenous immunoglobulins in polymyositis and dermatomyositis].
    Chérin P; Herson S
    Rev Med Interne; 1999; 20 Suppl 4():436s-439s. PubMed ID: 10522319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-D immunoglobulin-induced prolonged intravascular hemolysis and neutropenia.
    Alioglu B; Avci Z; Ozyurek E; Ozbek N
    J Pediatr Hematol Oncol; 2007 Sep; 29(9):636-9. PubMed ID: 17805040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adverse effect of polyvalent immunoglobulin in the treatment of Guillain-Barre syndrome.
    Chamouni P; Tamion F; Gueit I; Girault C; Lenain P; Varin R; Czernichow P
    Transfus Apher Sci; 2003 Apr; 28(2):117-24. PubMed ID: 12679114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ceftriaxone-induced hemolytic anemia in a child successfully managed with intravenous immunoglobulin.
    Vehapoğlu A; Göknar N; Tuna R; Çakır FB
    Turk J Pediatr; 2016; 58(2):216-219. PubMed ID: 27976566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mycoplasma pneumoniae infection associated with hemolytic anemia--report of one case.
    Wang JL; Ho MY; Shen EY
    Acta Paediatr Taiwan; 2004; 45(5):293-5. PubMed ID: 15868814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Post-marketing observational study on 5% intravenous immunoglobulin therapy in patients with secondary immunodeficiency and recurrent serious bacterial infections.
    Günther G; Dreger B
    Microbiol Immunol; 2013 Jul; 57(7):527-35. PubMed ID: 23607863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.